10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Thursday, March 29, 2012

Divis Laboratories Ltd:Buy/sell/growth prospects and recommendation,news and results,target and analysis,view and outlook,multibagger

Scripscan:Divis Laboratories Ltd

ML research:Divi’s Laboratories is an R&D player in the pharma space and has taken the less risky route of contract research and manufacturing, rather than patent challenges. It makes bulk drug ingredients and intermediate products for generic drugs. It is also involved in custom synthesis of bulk drug ingredients, building blocks for peptides and nucleotides, carotenoids, etc.The company initially focused on developing new processes for the production of active pharma ingredients (APIs) and intermediates. It, however, expanded its operations to provide complete turnkey solutions to the domestic pharmaceuticals industry. Riding on this experience, it established a foothold as a frontline manufacturer of APIs and intermediate chemicals for generic drugs. It has been able to do much better than its larger counterparts because of its ability to penetrate deeper into an expanded domestic market.Divi’s earned a total income of Rs366 crore on a standalone basis for the quarter ended 30 September 2011 against Rs257 crore for quarter ended 30 September 2010. Profit after tax (PAT) for the September quarter came to Rs106 crore against Rs73 crore, reflecting a growth of 45%. For the half-year ended 30 September 2011, total income was Rs731 crore compared to Rs522 crore. PAT for the September half-year was Rs209 crore as against Rs159 crore in the previous comparable half-year. The sharp depreciation of the rupee against the dollar (15%) in the December 2011 quarter is likely to help Divi’s Laboratories. The outlook for the sector continues to be good, given the opportunities in the US and emerging markets and the growth potential in the domestic pharma sector. A new facility called ‘DSN SEZ Unit’ is being set up at the company’s pharma SEZ (special economic zone) at village Chippada (Andhra Pradesh) at an estimated cost of Rs200 crore. This facility has been commissioned in the current year. Analysts at Bank of America Merrill Lynch see it growing to yield Rs400 crore of revenue, over the next two years. For FY10-11, Divi’s Laboratories had an income of Rs1,344 crore compared to Rs960 crore in FY09-10. PAT was Rs436 crore in the year ending March 2011 compared to Rs344 crore in the previous year—a growth of 27%. Earnings per share (EPS) of the company in FY10-11 were Rs32.90 against Rs26.40 in the previous year. Exports constituted 93% of total turnover in 2010-11 against 91% during the previous year. Dividend for the year 2010-11 was Rs10 per share of Rs2, i.e., a dividend of 500%.The outlook for the pharma sector continues to be good. The US and emerging markets offer attractive opportunities; growth is expected in the domestic pharma space as well. Over the past five quarters, Divi’s average growth in revenues and operating profit was 41% and 27%, respectively. Its average operating margin is 38% and return on net worth is 24%. Its market-cap to revenues is 7.06, while its market-cap to operating profit is 18.71 times. The stock is expensive by our parameters but it’s a growth stock and may not correct much. One can buy the stock at around Rs690.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner